We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and central nervous system disorders. We are focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept studies in 2019. In addition, Auris Medical has two Phase 3 programs under development: SonsuviÂŽ (AM-111) for acute inner ear hearing loss and KeyzilenÂŽ (AM-101) for acute inner ear tinnitus. SonsuviÂŽ (AM-111) has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. Source
No articles found.
Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancin...
Intersect ENT (NASDAQ: XENT) is a medical techn...
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focu...
Paratek Pharmaceuticals, Inc. is a commercial-s...
Catasys has contracted with leading national, regional and local health insurance ...
Catasys has contracted with leading national, r...
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing d...
Intec Pharma is a clinical-stage biopharmaceuti...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceuti...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a s...
Join the National Investor Network and get the latest information with your interests in mind.